Mitotane after adrenal tumor surgery, with or without chemo
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at whether giving mitotane after surgery (and possibly adding cisplatin/etoposide chemotherapy) helps prevent adrenal cancer from coming back. It is for people with stage I–III adrenal cortical cancer who have a high risk of relapse after their tumor was removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adrenal cortical cancer confirmed by pathology (Weiss score 3 or higher).
- Your cancer is considered high risk to come back within 90 days after curative-intent surgery (or margins are R1/RX).
- Your pre-randomization scans (CT/MRI or PET-CT) show no clear remaining cancer, within 8 weeks, and small “indeterminate” spots may be allowed.
- You can do daily activities fairly well (ECOG performance status 0–2) and you can follow study visits and procedures.
- Your blood counts and organ function are sufficient: kidneys (GFR ≥50), liver tests not too high, neutrophils ≥1000, and platelets ≥100,000.
- You are not pregnant or breastfeeding, and you have not had certain prior treatments for this cancer (like mitotane, ACC chemo, or radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving radiation before surgery helps people with adrenal cancer that has come back after previous treatment. It aims to see if this approach can improve outcomes for patients who can have surgery at the NIH.
This Phase 2 trial tests whether adding progesterone to standard chemotherapy improves outcomes for people with adrenal cortical carcinoma (ACC) that is locally advanced or has spread and cannot be removed with surgery. It also checks whether the treatment is safe and tolerable.
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
This study compares the use of radiation therapy after surgery versus simply monitoring for patients with high-risk adrenocortical carcinoma (ACC) that hasn't spread. The goal is to see if radiation helps prevent the cancer from coming back.
Hear when a new ENSAT Stage I Adrenal Cortex Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.